Pfizer lung cancer drug looks promising in mid-stage study

Pfizer's experimental lung cancer drug PF-299 has garnered some positive reviews after the pharma giant unveiled some promising, though preliminary, mid-stage data. Nearly 85 percent of the patients sharing an EGFR mutation were progress-free after about nine months of therapy.

While researchers have only tracked 74 patients so far, Pfizer is hoping that PF-299 could eventually be added to the pharmaceutical armory used to fight non-small cell lung cancer. Chinese University's Tony Mok says the drug is particularly promising because it can target multiple receptors on the HER pathway, notes Reuters and PharmaTimes, specifically HER 1(EGFR), HER-2 and HER-4.

"It also inhibits signalling in both wild-type and mutant EGFR, including forms of NSCLC that are resistant to EGFR inhibitors such as erlotinib and gefitinib," Mok adds.

- here's the story from Reuters
- and here's the PharmaTimes piece

Suggested Articles

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.

Johns Hopkins researchers developed a biodegradable polymer to transport large therapies into cells—including genes and even CRISPR.

UCB’s bispecific antibody recently beat Johnson & Johnson’s Stelara at clearing psoriasis symptoms, and now it has bested AbbVie’s Humira, too.